Introduction
Pulmonary regurgitation (PR) is common after tetralogy of Fallot (TOF) surgical repair. It is increasingly recognized that right-sided valve disease is not a benign lesion and that it has a significant and an independent impact on morbidity and mortality. 1 Surgical procedure often involves pulmonary valvulotomy, a transannular patch, or incision in the right ventricular (RV) infundibulum, which can all contribute to long-term PR. 2 Despite being well tolerated for a long time,
there is evidence that PR leads to progressive RV dilatation and eccentric hypertrophy. With time, it can be conducive to RV dysfunction, exercise intolerance, ventricular arrhythmias, and, rarely, a sudden cardiac death. 3 Dilatation and failure of the RV can be prevented by valve replacement. 4 Surgical bioprosthetic valves will eventually degenerate. In pulmonary position, this can be expected to occur 5-10 years after implantation. 5 Apart from valve degeneration, endocarditis can also be the cause of pulmonary valve (PV) failure. Valve thrombosis is considered rare. 6 Long-term anticoagulant therapy for tissue valves is not indicated. 7 There is, however, a positive effect on biological valve thrombosis, when there is a suspicion of it. 8 There is so far no evidence of any positive influence of novel oral anticoagulants (NOACs) on valvular thrombus formation.
We present a case of surgical tissue PV obstruction caused by a big thrombus in a patient on anticoagulation therapy with rivaroxaban.
Timeline Case presentation
A 33-year-old female patient was admitted to our Clinic with severe heart failure. She was referred for the first time 2 years earlier, as an emergency, for atrial flutter, frequency 215/min. An immediate cardioversion was performed, followed by electrophysiology and radiofrequency ablation and anticoagulant therapy with NOACs was introduced for paroxysmal atrial fibrillation (AF).
The young woman is an adult congenital heart disease patient, after surgical correction of TOF at the age of 4 years. She underwent ventricular septal defect (VSD) closure, right ventricle outflow tract resection, and PV repair with a Dacron annular patch. She has regularly been followed by an adult cardiologist without expertise in congenital heart disease.
At her first presentation in our hospital, echocardiographic (ECHO) examination revealed a dilated RV with already reduced systolic function and volume overload, dilated tricuspid annulus, and intermediate tricuspid regurgitation, with no evidence of residual VSD, obstruction of PV and pulmonary hypertension. A significant PR was observed, confirmed by cardiac magnetic resonance imaging, with regurgitation fraction of 41% and diastolic volume of the RV of 233 mL (116 mL/m One year and a half after the surgery, the clinical course was uneventful. The patient was treated by anticoagulation therapy with warfarin 3 months after surgery, followed by rivaroxaban 20 mg daily, for paroxysmal AF.
She arrived again 18 months later, with right heart failure, after a month of progressive effort intolerance. The ECHO revealed again the dilatation of RV, this time with signs of pressure overload, and pulmonary pressure gradient of 110 mmHg ( Figure 1) . Transoesophageal ECHO (TOE) established an organized thrombus formation on the prosthesis, measuring 25 Â 10 mm with an additional floating formation of 8 Â 5 mm and a residual valve 'tunnel' of $8 mm (Figure 2) . The findings of electrocardiogram-triggered pulmonary computed tomography (CT) angiography were similar ( Figure 3A and B) . We did not found thrombophilia, or a mechanical reason for valve thrombosis.
Reoperation was proposed and performed: excision of a thrombosed tissue valve and re-implantation of St. Jude Biocor valve A 25 mm, in pulmonary position. The patient made a good postoperative recovery. A long-term anticoagulation therapy with warfarin was induced. Postoperative ECHO showed reduction of RV volume and an improvement in systolic function. The PV gradient was 25 mmHg. The 9-month follow-up was uneventful.
Discussion
Pulmonary valve replacement after repair of TOF is recommended before the occurrence of RV dysfunction, but the timing is still 
controversial. Cardiac magnetic resonance imaging has become accepted as the gold standard for the assessment of RV remodelling. 9 Despite RV diastolic volume was less than recommended for PV replacement, considering our patients RV volume overload, along with rhythm disturbances, a decision for PV replacement was made.
The effects of PR on some electrocardiographic predictors of arrhythmia, for example AF, are not clear. Restoration of PV competence often leads to stabilization or reduction of QRS duration with a corresponding decrease in arrhythmia. 10 In our case, the atrial flutter was the first presentation of hemodynamic deterioration, a long time after TOF repair. Data concerning the best tissue valve prosthesis for use in the pulmonary position are scarce. 11 Literature describes several factors which influence the time of valve degeneration: the timing of surgery, Bio-prosthetic valve thrombosis is a rare event, which may occur late after surgery. 13 Patients with tissue heart valve prosthesis still have a risk of developing valve thrombosis and arterial thromboembolism. Antithrombotic therapy with warfarin in the early postoperative period is controversial, but still recommended. 14 Our patient was treated with warfarin for up to three months following surgery, whereupon rivaroxaban was introduced, for long-term thromboembolic protection after paroxysmal AF.
In patients with AF, rivaroxaban was not inferior to warfarin for the prevention of stroke or systemic embolism. 15 Although there is no evidence of NOAC activity in thrombotic events in valve disease, presence of any valvular disease did not influence the comparison of dabigatran with warfarin, and no difference in events was found. 16 A fixed-dose regimen of rivaroxaban alone showed no inferiority to standard therapy for the initial and long-term treatment of pulmonary embolism and had a potentially improved risk benefit profile. Novel oral anticoagulants appear to be safe and effective in adult patients with congenital heart disease. 17 There are no published data about influence of rivaroxaban or other NOACs on thrombotic events related to surgical tissue valves. Echocardiographic plays an important role to the diagnosis of biological valve thrombosis and CT may be of added value. 18 In our patient, PV thrombosis was first revealed by TOE, and then confirmed by CT. Bioprosthetic valves are generally considered to carry a low risk of thrombosis and only few reports exist of the valve thrombosis. Majority data refer to left heart mechanical valves thrombosis. 19 For the management, thrombolytic therapy has been suggested as an alternative to surgery. It is associated with lower mortality rate but carries the risk of embolism, bleeding, and re-thrombosis. The optimal treatment of biological valve thrombosis is still a matter of debate. Anticoagulation and operative intervention are the mainstay of treatment. A response to anticoagulation therapy is usually observed 4-12 weeks after initiation. 13 In our case, repeated surgery was performed, expecting complete haemodynamic success in a patient with high functional class, big thrombus burden, severe valve obstruction and low surgical risk. 20 
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